JP2002535007A - Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉの増殖に必要であると同定された遺伝子 - Google Patents
Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉの増殖に必要であると同定された遺伝子Info
- Publication number
- JP2002535007A JP2002535007A JP2000596147A JP2000596147A JP2002535007A JP 2002535007 A JP2002535007 A JP 2002535007A JP 2000596147 A JP2000596147 A JP 2000596147A JP 2000596147 A JP2000596147 A JP 2000596147A JP 2002535007 A JP2002535007 A JP 2002535007A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- growth
- gene
- cell
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 533
- 230000012010 growth Effects 0.000 title claims abstract description 328
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 139
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 374
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 293
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 293
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 120
- 230000014509 gene expression Effects 0.000 claims abstract description 91
- 244000005700 microbiome Species 0.000 claims abstract description 86
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 67
- 230000027455 binding Effects 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 304
- 238000000034 method Methods 0.000 claims description 274
- 230000000692 anti-sense effect Effects 0.000 claims description 206
- 150000001875 compounds Chemical class 0.000 claims description 196
- 230000000694 effects Effects 0.000 claims description 116
- 230000002401 inhibitory effect Effects 0.000 claims description 81
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 81
- 230000003115 biocidal effect Effects 0.000 claims description 73
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 72
- 229920001184 polypeptide Polymers 0.000 claims description 67
- 238000012360 testing method Methods 0.000 claims description 65
- 230000001580 bacterial effect Effects 0.000 claims description 63
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 59
- 108091034117 Oligonucleotide Proteins 0.000 claims description 49
- 239000012634 fragment Substances 0.000 claims description 49
- 241000894007 species Species 0.000 claims description 48
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 45
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 45
- 239000000523 sample Substances 0.000 claims description 43
- 239000000411 inducer Substances 0.000 claims description 39
- 230000037361 pathway Effects 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 35
- 239000013612 plasmid Substances 0.000 claims description 33
- 230000010261 cell growth Effects 0.000 claims description 30
- 108020004999 messenger RNA Proteins 0.000 claims description 30
- 108091026890 Coding region Proteins 0.000 claims description 29
- 230000035755 proliferation Effects 0.000 claims description 28
- 230000000295 complement effect Effects 0.000 claims description 26
- 210000000349 chromosome Anatomy 0.000 claims description 22
- 230000009036 growth inhibition Effects 0.000 claims description 20
- 230000001939 inductive effect Effects 0.000 claims description 20
- 241000607142 Salmonella Species 0.000 claims description 19
- 230000008236 biological pathway Effects 0.000 claims description 18
- 238000013518 transcription Methods 0.000 claims description 18
- 230000035897 transcription Effects 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 241000191967 Staphylococcus aureus Species 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 241000222122 Candida albicans Species 0.000 claims description 14
- 241000193155 Clostridium botulinum Species 0.000 claims description 14
- 241000194032 Enterococcus faecalis Species 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 14
- 229940095731 candida albicans Drugs 0.000 claims description 14
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 13
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 13
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 13
- 241000589884 Treponema pallidum Species 0.000 claims description 13
- 241000607479 Yersinia pestis Species 0.000 claims description 13
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 13
- 229940081969 saccharomyces cerevisiae Drugs 0.000 claims description 13
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 12
- 241000606768 Haemophilus influenzae Species 0.000 claims description 12
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 12
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 241000606161 Chlamydia Species 0.000 claims description 11
- 201000007336 Cryptococcosis Diseases 0.000 claims description 11
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 11
- 241000588697 Enterobacter cloacae Species 0.000 claims description 11
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 11
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 11
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 11
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 11
- 229940091771 aspergillus fumigatus Drugs 0.000 claims description 11
- 241000186362 Mycobacterium leprae Species 0.000 claims description 10
- 241000193738 Bacillus anthracis Species 0.000 claims description 9
- 241000589875 Campylobacter jejuni Species 0.000 claims description 9
- 241000590002 Helicobacter pylori Species 0.000 claims description 9
- 229940037467 helicobacter pylori Drugs 0.000 claims description 9
- 230000003287 optical effect Effects 0.000 claims description 9
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 8
- 229940065181 bacillus anthracis Drugs 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- 230000001235 sensitizing effect Effects 0.000 claims description 8
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 8
- 108091092724 Noncoding DNA Proteins 0.000 claims description 7
- 230000000813 microbial effect Effects 0.000 claims description 7
- 108090000994 Catalytic RNA Proteins 0.000 claims description 6
- 102000053642 Catalytic RNA Human genes 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 108091092562 ribozyme Proteins 0.000 claims description 6
- 241001647372 Chlamydia pneumoniae Species 0.000 claims description 5
- 210000004102 animal cell Anatomy 0.000 claims description 5
- 238000004422 calculation algorithm Methods 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 5
- 241000589876 Campylobacter Species 0.000 claims description 4
- 206010008631 Cholera Diseases 0.000 claims description 4
- 241000588748 Klebsiella Species 0.000 claims description 4
- 241000588653 Neisseria Species 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 230000004543 DNA replication Effects 0.000 claims description 3
- 108091030145 Retron msr RNA Proteins 0.000 claims description 3
- 206010070834 Sensitisation Diseases 0.000 claims description 3
- 230000032823 cell division Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- 230000008313 sensitization Effects 0.000 claims description 3
- 230000001851 biosynthetic effect Effects 0.000 claims description 2
- 150000001722 carbon compounds Chemical class 0.000 claims description 2
- 230000005758 transcription activity Effects 0.000 claims description 2
- 108091092194 transporter activity Proteins 0.000 claims description 2
- 102000040811 transporter activity Human genes 0.000 claims description 2
- 241001478240 Coccus Species 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 150000008195 galaktosides Chemical class 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 abstract description 59
- 239000013604 expression vector Substances 0.000 abstract description 54
- 238000003556 assay Methods 0.000 abstract description 37
- 238000012216 screening Methods 0.000 abstract description 19
- 238000013461 design Methods 0.000 abstract description 5
- 239000013606 secretion vector Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 82
- 238000003752 polymerase chain reaction Methods 0.000 description 48
- 108700028369 Alleles Proteins 0.000 description 42
- 239000003814 drug Substances 0.000 description 35
- 101150098466 rpsL gene Proteins 0.000 description 31
- 229940079593 drug Drugs 0.000 description 29
- 230000006870 function Effects 0.000 description 28
- 239000002609 medium Substances 0.000 description 28
- 230000035945 sensitivity Effects 0.000 description 25
- 230000014616 translation Effects 0.000 description 25
- 241000894006 Bacteria Species 0.000 description 23
- 229920002477 rna polymer Polymers 0.000 description 23
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 21
- 108020005544 Antisense RNA Proteins 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 239000004098 Tetracycline Substances 0.000 description 18
- 238000000423 cell based assay Methods 0.000 description 18
- 239000003184 complementary RNA Substances 0.000 description 18
- 229960002180 tetracycline Drugs 0.000 description 18
- 229930101283 tetracycline Natural products 0.000 description 18
- 235000019364 tetracycline Nutrition 0.000 description 18
- 150000003522 tetracyclines Chemical class 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229960005091 chloramphenicol Drugs 0.000 description 14
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 238000013519 translation Methods 0.000 description 13
- 108091093037 Peptide nucleic acid Proteins 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 238000001243 protein synthesis Methods 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 101100311054 Salmonella choleraesuis (strain SC-B67) sseL gene Proteins 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 9
- 101150109029 elaD gene Proteins 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000006801 homologous recombination Effects 0.000 description 9
- 238000002744 homologous recombination Methods 0.000 description 9
- 108700039887 Essential Genes Proteins 0.000 description 8
- 108010000605 Ribosomal Proteins Proteins 0.000 description 8
- 239000004599 antimicrobial Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000007876 drug discovery Methods 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 101000575173 Homo sapiens 60S ribosomal protein L12 Proteins 0.000 description 7
- 101000659995 Homo sapiens Ribosomal L1 domain-containing protein 1 Proteins 0.000 description 7
- 102000002278 Ribosomal Proteins Human genes 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 230000002759 chromosomal effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 102100025643 60S ribosomal protein L12 Human genes 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 102100021546 60S ribosomal protein L10 Human genes 0.000 description 5
- 108700003860 Bacterial Genes Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000589989 Helicobacter Species 0.000 description 5
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 5
- 241000186359 Mycobacterium Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 101150025220 sacB gene Proteins 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 108010077805 Bacterial Proteins Proteins 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 201000005019 Chlamydia pneumonia Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 101100290629 Escherichia coli (strain K12) mdtQ gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 3
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 101150026213 atpB gene Proteins 0.000 description 3
- 101150035600 atpD gene Proteins 0.000 description 3
- 101150038923 atpF gene Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003596 drug target Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007852 inverse PCR Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000001823 molecular biology technique Methods 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 210000001322 periplasm Anatomy 0.000 description 3
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 102000016559 DNA Primase Human genes 0.000 description 2
- 108010092681 DNA Primase Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010006296 DnaB Helicases Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000224432 Entamoeba histolytica Species 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- 108010054278 Lac Repressors Proteins 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 2
- 108010077742 Peptide Elongation Factor G Proteins 0.000 description 2
- 102000010562 Peptide Elongation Factor G Human genes 0.000 description 2
- 101710205263 Peptidoglycan D,D-transpeptidase MrdA Proteins 0.000 description 2
- 241001505293 Plasmodium ovale Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101710116427 Probable peptidoglycan D,D-transpeptidase PenA Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- NAXKFVIRJICPAO-LHNWDKRHSA-N [(1R,3S,4R,6R,7R,9S,10S,12R,13S,15S,16R,18S,19S,21S,22S,24S,25S,27S,28R,30R,31R,33S,34S,36R,37R,39R,40S,42R,44R,46S,48S,50R,52S,54S,56S)-46,48,50,52,54,56-hexakis(hydroxymethyl)-2,8,14,20,26,32,38,43,45,47,49,51,53,55-tetradecaoxa-5,11,17,23,29,35,41-heptathiapentadecacyclo[37.3.2.23,7.29,13.215,19.221,25.227,31.233,37.04,6.010,12.016,18.022,24.028,30.034,36.040,42]hexapentacontan-44-yl]methanol Chemical compound OC[C@H]1O[C@H]2O[C@H]3[C@H](CO)O[C@H](O[C@H]4[C@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]6[C@H](CO)O[C@H](O[C@H]7[C@H](CO)O[C@@H](O[C@H]8[C@H](CO)O[C@@H](O[C@@H]1[C@@H]1S[C@@H]21)[C@@H]1S[C@H]81)[C@H]1S[C@@H]71)[C@H]1S[C@H]61)[C@H]1S[C@@H]51)[C@H]1S[C@@H]41)[C@H]1S[C@H]31 NAXKFVIRJICPAO-LHNWDKRHSA-N 0.000 description 2
- 229940024554 amdinocillin Drugs 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 101150076598 dnaB gene Proteins 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940007078 entamoeba histolytica Drugs 0.000 description 2
- 230000009483 enzymatic pathway Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 238000000424 optical density measurement Methods 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 210000004708 ribosome subunit Anatomy 0.000 description 2
- 101150021143 rplW gene Proteins 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940043263 traditional drug Drugs 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LVPXMPVIIAGLBC-KHUXNXPUSA-N (2r,3s)-2-(hydroxymethyl)-5-phenyloxolan-3-ol Chemical compound C1[C@H](O)[C@@H](CO)OC1C1=CC=CC=C1 LVPXMPVIIAGLBC-KHUXNXPUSA-N 0.000 description 1
- NSMOSDAEGJTOIQ-CRCLSJGQSA-N (2r,3s)-2-(hydroxymethyl)oxolan-3-ol Chemical compound OC[C@H]1OCC[C@@H]1O NSMOSDAEGJTOIQ-CRCLSJGQSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical group NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102100021308 60S ribosomal protein L23 Human genes 0.000 description 1
- 102100035841 60S ribosomal protein L7 Human genes 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- OCOCOMKPKKQRTM-UHFFFAOYSA-N 9-methyl-1,5,7-triazaspiro[3.5]non-8-en-6-one Chemical compound CC=1C2(NC(NC=1)=O)NCC2 OCOCOMKPKKQRTM-UHFFFAOYSA-N 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100282111 Caenorhabditis elegans gap-2 gene Proteins 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102100033040 Carbonic anhydrase 12 Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241001058146 Erium Species 0.000 description 1
- 101100539305 Escherichia coli (strain K12) ubiI gene Proteins 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101100321669 Fagopyrum esculentum FA02 gene Proteins 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000853617 Homo sapiens 60S ribosomal protein L7 Proteins 0.000 description 1
- 101000867855 Homo sapiens Carbonic anhydrase 12 Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101150046735 LEPR gene Proteins 0.000 description 1
- 101150063827 LEPROT gene Proteins 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 101000735344 Lymantria dispar Pheromone-binding protein 2 Proteins 0.000 description 1
- 101150028955 MBP gene Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101710197992 Penicillin-binding protein PbpB Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108090000986 Ribosomal protein L10 Proteins 0.000 description 1
- 108050001924 Ribosomal protein L23 Proteins 0.000 description 1
- 102000008837 Ribosomal protein L7/L12 Human genes 0.000 description 1
- 108050000743 Ribosomal protein L7/L12 Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000256215 Spongomorpha aeruginosa Species 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101100093927 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) rspG gene Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 229910052614 beryl Inorganic materials 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940015062 campylobacter jejuni Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002809 confirmatory assay Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 229940119563 enterobacter cloacae Drugs 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 101150111615 ftsZ gene Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 101150106875 malE gene Proteins 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000007939 microbial gene expression Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000012514 monoclonal antibody product Substances 0.000 description 1
- 101150064202 mrdA gene Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229950011346 panipenem Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 230000027086 plasmid maintenance Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108010037046 ribosomal protein L7-L12 Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 101150111766 sc gene Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229940037645 staphylococcus epidermidis Drugs 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 101150099542 tuf gene Proteins 0.000 description 1
- 101150071165 tuf1 gene Proteins 0.000 description 1
- 101150010742 tuf2 gene Proteins 0.000 description 1
- 101150061352 tufA gene Proteins 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11740599P | 1999-01-27 | 1999-01-27 | |
| US60/117,405 | 1999-01-27 | ||
| PCT/US2000/002200 WO2000044906A2 (fr) | 1999-01-27 | 2000-01-27 | Genes identifies intervenant dans la proliferation cellulaire d'escherichia coli |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002535007A true JP2002535007A (ja) | 2002-10-22 |
Family
ID=22372748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596147A Pending JP2002535007A (ja) | 1999-01-27 | 2000-01-27 | Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉの増殖に必要であると同定された遺伝子 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1149166A2 (fr) |
| JP (1) | JP2002535007A (fr) |
| KR (1) | KR20010101861A (fr) |
| AU (1) | AU3584500A (fr) |
| CA (1) | CA2360085A1 (fr) |
| NZ (1) | NZ512835A (fr) |
| WO (1) | WO2000044906A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007013411A1 (fr) * | 2005-07-25 | 2007-02-01 | Kaneka Corporation | Acide nucléique antisens dérivé d'un organisme |
| JP2009506773A (ja) * | 2005-09-01 | 2009-02-19 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | メラノサイト刺激ホルモンペプチド模倣体 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1130094A3 (fr) * | 1999-07-08 | 2001-11-21 | Helix Research Institute | Amorces pour la synthèse de cADN de pleine longueur et leur utilisation |
| EP1220903A1 (fr) * | 1999-10-13 | 2002-07-10 | Pantheco A/S | Selection de genes utilisant des sequences de pna |
| US6783985B1 (en) | 2000-02-18 | 2004-08-31 | Elitra Pharmaceuticals Inc. | Gene disruption methodologies for drug target discovery |
| WO2002079467A2 (fr) * | 2001-03-29 | 2002-10-10 | Københavns Universitet | Selection de souche bacterienne sans antibiotique a l'aide de molecules antisens |
| US20030082591A1 (en) * | 2001-07-24 | 2003-05-01 | Donald Awrey | Methods for gene disruption and uses thereof |
| FR2842210B1 (fr) * | 2002-07-09 | 2012-12-14 | Mutabilis | Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique |
| US20120301434A1 (en) * | 2009-10-02 | 2012-11-29 | Oslo Universitetssykehus Hf | Antibacterial polypeptides and use thereof |
| US9090928B2 (en) * | 2010-10-07 | 2015-07-28 | Yale University | Site-specific incorporation of phosphoserine into proteins in Escherichia coli |
| US9464288B2 (en) | 2011-07-11 | 2016-10-11 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| US11788111B2 (en) | 2011-07-11 | 2023-10-17 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| US10240158B2 (en) | 2011-07-11 | 2019-03-26 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| US10876142B2 (en) | 2011-07-11 | 2020-12-29 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| CA3127177A1 (fr) * | 2019-01-31 | 2020-08-06 | Spiber Inc. | Procede de production d'une proteine de recombinaison |
| CN113917140B (zh) * | 2021-10-28 | 2023-08-18 | 生工生物工程（上海）股份有限公司 | 一种快速筛选原核蛋白表达菌的方法 |
| CN116218890A (zh) * | 2021-12-06 | 2023-06-06 | 深圳华大生命科学研究院 | 基因串联表达盒、多位点基因编辑系统及应用 |
| US11866728B2 (en) | 2022-01-21 | 2024-01-09 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0960212B1 (fr) * | 1996-11-13 | 2007-05-09 | Qbi Enterprises Ltd. | Procédé d'identification de gènes |
| US6610539B1 (en) * | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
-
2000
- 2000-01-27 NZ NZ512835A patent/NZ512835A/xx unknown
- 2000-01-27 CA CA002360085A patent/CA2360085A1/fr not_active Abandoned
- 2000-01-27 JP JP2000596147A patent/JP2002535007A/ja active Pending
- 2000-01-27 WO PCT/US2000/002200 patent/WO2000044906A2/fr not_active Application Discontinuation
- 2000-01-27 KR KR1020017009547A patent/KR20010101861A/ko not_active Application Discontinuation
- 2000-01-27 AU AU35845/00A patent/AU3584500A/en not_active Abandoned
- 2000-01-27 EP EP00914458A patent/EP1149166A2/fr not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007013411A1 (fr) * | 2005-07-25 | 2007-02-01 | Kaneka Corporation | Acide nucléique antisens dérivé d'un organisme |
| JP2009506773A (ja) * | 2005-09-01 | 2009-02-19 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | メラノサイト刺激ホルモンペプチド模倣体 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1149166A2 (fr) | 2001-10-31 |
| WO2000044906A2 (fr) | 2000-08-03 |
| NZ512835A (en) | 2004-02-27 |
| WO2000044906A3 (fr) | 2001-02-01 |
| AU3584500A (en) | 2000-08-18 |
| KR20010101861A (ko) | 2001-11-15 |
| CA2360085A1 (fr) | 2000-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4852211B2 (ja) | 原核生物における必須遺伝子の同定 | |
| US20040029129A1 (en) | Identification of essential genes in microorganisms | |
| JP2002535007A (ja) | Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉの増殖に必要であると同定された遺伝子 | |
| US6720139B1 (en) | Genes identified as required for proliferation in Escherichia coli | |
| WO2002077183A2 (fr) | Identification de genes essentiels dans des microorganismes | |
| JP2003518386A (ja) | 大腸菌の増殖に必要であることが同定された遺伝子 | |
| JP2002529046A (ja) | Ｅｎｔｅｒｏｃｏｃｃｕｓ ｆａｅｃａｌｉｓのポリヌクレオチドおよびポリペプチド | |
| JPH09507745A (ja) | 組換えＰｉｌＣタンパク質、それらの製造方法及び使用方法 | |
| KR20010033721A (ko) | 필수 세균 유전자 및 이의 용도 | |
| US6589738B1 (en) | Genes essential for microbial proliferation and antisense thereto | |
| JP2003520034A (ja) | ビルレンス遺伝子、タンパク質、およびそれらの用途 | |
| Melnikow et al. | A compendium of antibiotic-induced transcription profiles reveals broad regulation of Pasteurella multocida virulence genes | |
| US6764823B2 (en) | Antimicrobial methods and materials | |
| US20030170694A1 (en) | Stabilized nucleic acids in gene and drug discovery and methods of use | |
| US20050202424A1 (en) | Regulators of biofilm formation and uses thereof | |
| EP1178052A2 (fr) | Gènes identifies intervenant dans la prolifération cellulaire d'escherichia coli | |
| JP2002541820A (ja) | 抗菌性化合物を同定する新規な方法 | |
| US7390620B2 (en) | Screening method for anti-microbial drug targets by genome-saturating mutagenesis (GSM) | |
| US20020187544A1 (en) | Uropathogenic E. coli D-serine detoxification operon | |
| RU2240327C2 (ru) | Ген и белок вирулентности и их использование | |
| Jo | Two novel outer membrane proteins involved in intrinsic aminoglycoside resistence in Pseudomonas aeruginosa | |
| US20040137516A1 (en) | DNA sequences from staphylococcus aureus bacteriophage 44AHJD that encode anti-microbial polypeptides | |
| JP2003517833A (ja) | スタフィロコッカス・アウレウス必須遺伝子とそれにコードされるタンパク質に関連する組成物と方法 | |
| CZ20002465A3 (cs) | Esenciální bakteriální geny a jejich použití |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050311 |